How much did Eurobio Scientific achieve in EBIT for the current year?
In the current year, Eurobio Scientific has achieved an EBIT of 24 M EUR.
Eurobio Scientific EBIT 2024
Eurobio Scientific EBIT
24 M EUR
Ticker
ALERS.PA
ISIN
FR0013240934
WKN
A2DVTN
In 2024, Eurobio Scientific's EBIT was 24 M EUR, a 65.07% increase from the 14.54 M EUR EBIT recorded in the previous year.
The Eurobio Scientific EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2026e | 32.14 |
| 2025e | 27.81 |
| 2024e | 24 |
| 2023 | 14.54 |
| 2022 | 30.87 |
| 2021 | 70.12 |
| 2020 | 81.21 |
| 2019 | 0.57 |
| 2018 | -1.16 |
| 2017 | -5.79 |
| 2016 | -7.39 |
| 2015 | -8.34 |
| 2014 | -5.69 |
| 2013 | -7.03 |
| 2012 | -6.55 |
| 2011 | -8.1 |
| 2010 | -6.97 |
| 2009 | -9.66 |
| 2008 | -11.39 |
| 2007 | -7.79 |
| 2006 | -4.98 |
| 2005 | -4.84 |
| 2004 | -10.15 |
Eurobio Scientific Revenue, EBIT, Net Income FR0013240934 · A2DVTN
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Eurobio Scientific, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eurobio Scientific from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eurobio Scientific’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Eurobio Scientific. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Eurobio Scientific’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Eurobio Scientific’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eurobio Scientific’s growth potential.
Eurobio Scientific Revenue, EBIT and net profit per share
| Date | Eurobio Scientific Revenue | Eurobio Scientific EBIT | Eurobio Scientific Net Income |
|---|---|---|---|
| 2026e | 160.89 M undefined | 32.14 M undefined | 14.99 M undefined |
| 2025e | 152.54 M undefined | 27.81 M undefined | 11.72 M undefined |
| 2024e | 142.14 M undefined | 24 M undefined | 9.29 M undefined |
| 2023 | 130 M undefined | 14.54 M undefined | 4.84 M undefined |
| 2022 | 152.61 M undefined | 30.87 M undefined | 24.94 M undefined |
| 2021 | 184.71 M undefined | 70.12 M undefined | 60.54 M undefined |
| 2020 | 188.86 M undefined | 81.21 M undefined | 73.48 M undefined |
| 2019 | 59.07 M undefined | 569,000 undefined | 3.15 M undefined |
| 2018 | 50.54 M undefined | -1.16 M undefined | -2.77 M undefined |
| 2017 | 42.67 M undefined | -5.79 M undefined | -9.97 M undefined |
| 2016 | 27.72 M undefined | -7.39 M undefined | -7.73 M undefined |
| 2015 | 29.46 M undefined | -8.34 M undefined | -5.88 M undefined |
| 2014 | 30.62 M undefined | -5.69 M undefined | -5.49 M undefined |
| 2013 | 30.5 M undefined | -7.03 M undefined | -5.99 M undefined |
| 2012 | 5.39 M undefined | -6.55 M undefined | -5.77 M undefined |
| 2011 | 4.99 M undefined | -8.1 M undefined | -7.1 M undefined |
| 2010 | 8.42 M undefined | -6.97 M undefined | -7.75 M undefined |
| 2009 | 4.89 M undefined | -9.66 M undefined | -7.7 M undefined |
| 2008 | 4.22 M undefined | -11.39 M undefined | -8.93 M undefined |
| 2007 | 5.39 M undefined | -7.79 M undefined | -7.34 M undefined |
| 2006 | 5.64 M undefined | -4.98 M undefined | -4.53 M undefined |
| 2005 | 4.55 M undefined | -4.84 M undefined | -4.24 M undefined |
| 2004 | 4.23 M undefined | -10.15 M undefined | -11.47 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 4.23 M EUR | -10.15 M EUR | -11.47 M EUR |
| 2005 | 4.55 M EUR | -4.84 M EUR | -4.24 M EUR |
| 2006 | 5.64 M EUR | -4.98 M EUR | -4.53 M EUR |
| 2007 | 5.39 M EUR | -7.79 M EUR | -7.34 M EUR |
| 2008 | 4.22 M EUR | -11.39 M EUR | -8.93 M EUR |
| 2009 | 4.89 M EUR | -9.66 M EUR | -7.7 M EUR |
| 2010 | 8.42 M EUR | -6.97 M EUR | -7.75 M EUR |
| 2011 | 4.99 M EUR | -8.1 M EUR | -7.1 M EUR |
| 2012 | 5.39 M EUR | -6.55 M EUR | -5.77 M EUR |
| 2013 | 30.5 M EUR | -7.03 M EUR | -5.99 M EUR |
| 2014 | 30.62 M EUR | -5.69 M EUR | -5.49 M EUR |
| 2015 | 29.46 M EUR | -8.34 M EUR | -5.88 M EUR |
| 2016 | 27.72 M EUR | -7.39 M EUR | -7.73 M EUR |
| 2017 | 42.67 M EUR | -5.79 M EUR | -9.97 M EUR |
| 2018 | 50.54 M EUR | -1.16 M EUR | -2.77 M EUR |
| 2019 | 59.07 M EUR | 569,000 EUR | 3.15 M EUR |
| 2020 | 188.86 M EUR | 81.21 M EUR | 73.48 M EUR |
| 2021 | 184.71 M EUR | 70.12 M EUR | 60.54 M EUR |
| 2022 | 152.61 M EUR | 30.87 M EUR | 24.94 M EUR |
| 2023 | 130 M EUR | 14.54 M EUR | 4.84 M EUR |
| 2024e | 142.14 M EUR | 24 M EUR | 9.29 M EUR |
| 2025e | 152.54 M EUR | 27.81 M EUR | 11.72 M EUR |
| 2026e | 160.89 M EUR | 32.14 M EUR | 14.99 M EUR |
Eurobio Scientific stock margins FR0013240934 · A2DVTN
The Eurobio Scientific margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eurobio Scientific. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eurobio Scientific.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Eurobio Scientific's sales revenue. A higher gross margin percentage indicates that the Eurobio Scientific retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Eurobio Scientific's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Eurobio Scientific's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eurobio Scientific's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eurobio Scientific. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eurobio Scientific's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Eurobio Scientific Margin History
| Eurobio Scientific Gross margin | Eurobio Scientific Profit margin | Eurobio Scientific EBIT margin | Eurobio Scientific Profit margin |
|---|---|---|---|
| 2026e | 47.11 % | 19.97 % | 9.32 % |
| 2025e | 47.11 % | 18.23 % | 7.68 % |
| 2024e | 47.11 % | 16.88 % | 6.54 % |
| 2023 | 47.11 % | 11.18 % | 3.72 % |
| 2022 | 46.49 % | 20.23 % | 16.34 % |
| 2021 | 55.35 % | 37.96 % | 32.78 % |
| 2020 | 58.46 % | 43 % | 38.91 % |
| 2019 | 33.14 % | 0.96 % | 5.34 % |
| 2018 | 36.56 % | -2.29 % | -5.48 % |
| 2017 | 35.05 % | -13.56 % | -23.36 % |
| 2016 | 28.38 % | -26.66 % | -27.9 % |
| 2015 | 28.3 % | -28.31 % | -19.95 % |
| 2014 | 43.1 % | -18.58 % | -17.92 % |
| 2013 | 46.82 % | -23.05 % | -19.64 % |
| 2012 | 91.65 % | -121.52 % | -107.05 % |
| 2011 | 47.11 % | -162.32 % | -142.28 % |
| 2010 | 47.11 % | -82.78 % | -92.04 % |
| 2009 | 47.11 % | -197.55 % | -157.46 % |
| 2008 | 47.11 % | -269.91 % | -211.61 % |
| 2007 | 47.11 % | -144.53 % | -136.18 % |
| 2006 | 47.11 % | -88.3 % | -80.32 % |
| 2005 | 47.11 % | -106.37 % | -93.19 % |
| 2004 | 47.11 % | -239.95 % | -271.16 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 47.11 % | -239.95 % | -271.16 % |
| 2005 | 47.11 % | -106.37 % | -93.19 % |
| 2006 | 47.11 % | -88.3 % | -80.32 % |
| 2007 | 47.11 % | -144.53 % | -136.18 % |
| 2008 | 47.11 % | -269.91 % | -211.61 % |
| 2009 | 47.11 % | -197.55 % | -157.46 % |
| 2010 | 47.11 % | -82.78 % | -92.04 % |
| 2011 | 47.11 % | -162.32 % | -142.28 % |
| 2012 | 91.65 % | -121.52 % | -107.05 % |
| 2013 | 46.82 % | -23.05 % | -19.64 % |
| 2014 | 43.1 % | -18.58 % | -17.92 % |
| 2015 | 28.3 % | -28.31 % | -19.95 % |
| 2016 | 28.38 % | -26.66 % | -27.9 % |
| 2017 | 35.05 % | -13.56 % | -23.36 % |
| 2018 | 36.56 % | -2.29 % | -5.48 % |
| 2019 | 33.14 % | 0.96 % | 5.34 % |
| 2020 | 58.46 % | 43 % | 38.91 % |
| 2021 | 55.35 % | 37.96 % | 32.78 % |
| 2022 | 46.49 % | 20.23 % | 16.34 % |
| 2023 | 47.11 % | 11.18 % | 3.72 % |
| 2024e | 47.11 % | 16.88 % | 6.54 % |
| 2025e | 47.11 % | 18.23 % | 7.68 % |
| 2026e | 47.11 % | 19.97 % | 9.32 % |
Eurobio Scientific Aktienanalyse
What does Eurobio Scientific do?
Eurobio Scientific SA is a French company specializing in the development and marketing of diagnostic and research products in the field of biology. It was founded in 2007 as a spin-off from the Pierre and Marie Curie University and is headquartered in Paris. Since 2017, the company has been listed on Euronext Growth in Paris. The company's business model is based on clear divisional structure with various product lines, including clinical diagnostics, research diagnostics, blood bank diagnostics, food analysis, and animal health research. Eurobio Scientific SA operates in over 60 countries and has a strong presence in Europe and Asia. Its notable products include the COVID-19 antibody test ELISA, a rapid COVID-19 test based on immuno-chromatography, and an All-In-One PCR test system for detecting COVID-19. This system allows for the rapid identification of the virus through a single reaction tube. Overall, Eurobio Scientific SA is an innovative company committed to constant product development and improvement, and its diverse product portfolio and international presence highlight its strength and position as an emerging player in the field of diagnostic and research products. Eurobio Scientific ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Eurobio Scientific's EBIT
Eurobio Scientific's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Eurobio Scientific's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Eurobio Scientific's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Eurobio Scientific’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Eurobio Scientific stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Eurobio Scientific.
How has the EBIT of Eurobio Scientific developed in recent years?
The EBIT of Eurobio Scientific has increased by 65.066% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Eurobio Scientific?
The EBIT of Eurobio Scientific is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Eurobio Scientific pay?
Over the past 12 months, Eurobio Scientific paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eurobio Scientific is expected to pay a dividend of 0 EUR.
What is the dividend yield of Eurobio Scientific?
The current dividend yield of Eurobio Scientific is .
When does Eurobio Scientific pay dividends?
Eurobio Scientific pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Eurobio Scientific?
Eurobio Scientific paid dividends every year for the past 0 years.
What is the dividend of Eurobio Scientific?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Eurobio Scientific located?
Eurobio Scientific is assigned to the 'Health' sector.
Wann musste ich die Aktien von Eurobio Scientific kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Eurobio Scientific from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Eurobio Scientific pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Eurobio Scientific in the year 2023?
In the year 2023, Eurobio Scientific distributed 0 EUR as dividends.
In which currency does Eurobio Scientific pay out the dividend?
The dividends of Eurobio Scientific are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Eurobio Scientific
Our stock analysis for Eurobio Scientific Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eurobio Scientific Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Eurobio Scientific Revenue
- Eurobio Scientific Net Income
- Eurobio Scientific P/E
- Eurobio Scientific P/S
- Eurobio Scientific EBIT
- Eurobio Scientific Dividend
- Eurobio Scientific Stocks
- Eurobio Scientific Market capitalization
- Eurobio Scientific Debt
- Eurobio Scientific Liabilities
- Eurobio Scientific Equity
- Eurobio Scientific AAQS
- Eurobio Scientific Employees
- Eurobio Scientific ROE
- Eurobio Scientific ROA
- Eurobio Scientific ROCE
